MedTrace Logo

Pharmacokinetics of Piperacillin, Given as Continuous Infusion to Patients With Cystic Fibrosis

NCT01983787 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2015-12-11

Study results available
· View outcomes & findings →

Summary

At the Department of Infectious Diseases, Aarhus University Hospital, continuous infusion with piperacillin/tazobactam for a period of 2 weeks, has been used for several years in patients with cystic fibrosis, suffering from acute pulmonary exacerbations (APE).

It is an outpatient treatment. To assess the efficacy and quality of the treatment, a blood test every 3rd day is taken to determine the concentration of Piperacillin in blood-plasma.

Conditions

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Eskild Petersen, Professor · Department of Infectious Diseases, Aarhus University Hospital, Denmark

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01983787 on ClinicalTrials.gov